Development of a Phase III Allogeneic Cell Therapy Manufacturing Process – ARM Meeting on the Mesa 2024 Presentation
DiscGenics’ 2024 Meeting on the Mesa presentation on scaling an allogeneic disc progenitor cell therapy to Phase III, including a human-component-free culture supplement with Cellastim S rHSA and Optiferrin transferrin and an excipient cryopreservation formulation with Exbumin rHSA.
Published
Nov 2026